If you are considering ChondroFiller, it helps to understand what it actually does inside the joint. ChondroFiller is a non-surgical, ultrasound-guided intra-articular collagen injection — a collagen-based gel placed into the joint as an outpatient procedure. This article explains, in plain terms, how it is thought to work, with realistic expectations throughout.

What Is ChondroFiller?

ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is based on type I collagen, a natural structural protein. The device arrives as two components in a sterile double-chamber syringe; when mixed during the injection, they form a soft, self-gelling scaffold at body temperature. Gelation typically completes within three to five minutes.

Given as an ultrasound-guided injection into the joint, the gel fills the contours of the cartilage defect and adheres to the surrounding tissue without sutures or surgical fixation. Because no incision or anaesthetic is required, it is carried out as an outpatient procedure. Joints most commonly treated include the knee, hip, ankle, and smaller joints such as the thumb base.

A Cushioning, Protective Role

Once in place, the gel may provide a protective interface between worn surfaces, helping to cushion the joint and reduce direct grinding and contact. Its structure allows it to absorb load and adapt to the mechanical forces inside a joint (Weizel et al., 2020), which is part of how it may ease symptoms during movement. Importantly, it stays in place without stitches and without any surgical intervention.

Biological Potential — With Realistic Expectations

The therapeutic principle behind ChondroFiller is acellular matrix-induced chondrogenesis: the scaffold itself is cell-free, but it is designed to attract the body's own progenitor cells from the surrounding synovium and subchondral bone into the defect. Once recruited, these cells can migrate into the scaffold, differentiate into chondrocyte-like cells, and begin producing new cartilage matrix components, including type II collagen characteristic of hyaline cartilage. Over a period of one to two years, the collagen scaffold is gradually resorbed and replaced by this patient-derived repair tissue.

Because it works in harmony with the joint's own biology rather than simply masking pain, ChondroFiller is best understood as a regenerative, joint-preserving injection. However, it is not a guaranteed repair. It is not a cure for arthritis, does not reverse joint degeneration, and the extent to which new cartilage-like tissue forms varies between people. How much it helps, and for how long, depends on the individual, the joint, and the size and grade of the defect.

What the Evidence Suggests

Clinical evidence for ChondroFiller spans multiple joints. In the knee, published series report IKDC scores improving by approximately 30 points over 12 to 36 months. In the hip, modified Harris Hip Score improvements of over 30 points have been observed. MRI assessment using MOCART scoring — which evaluates cartilage repair tissue quality — has reached around 80 and above in knee and hip studies, indicating high-quality defect fill. These outcomes come from the device's clinical evaluation programme and from independent literature.

A 2023 study of an acellular collagen matrix injection for thumb-base osteoarthritis reported improvements in pain and grip strength (Corain et al., 2023), demonstrating that the approach extends beyond the major weight-bearing joints. As with any developing treatment, larger and longer studies are needed to confirm how well and how durably the benefits are sustained across different patient populations.

The safety record is notable: across more than 19,000 units sold since 2013, no serious device-related incidents have been reported, and the overall complaint rate is exceptionally low.

How ChondroFiller Differs From Surgical Cartilage Procedures

It is worth distinguishing ChondroFiller as an injection from surgical cartilage restoration. ChondroFiller delivered by injection is a non-surgical, outpatient procedure requiring no theatre, no general anaesthetic, and no surgical incision. It is suited to accessible defects and smaller or moderate lesions where the injection can be accurately placed under ultrasound guidance.

For larger or more complex defects — particularly in major load-bearing joints such as the knee, hip, or shoulder — a surgical approach may be more appropriate. The London Cartilage Clinic also offers the Lee Liquid Cartilage Protocol, a keyhole arthroscopic surgical procedure in which the ChondroFiller scaffold is placed under direct vision alongside biological adjuncts such as platelet-rich fibrin and, where indicated, the patient's own mesenchymal stem cells. This is a separate, genuinely surgical procedure — not the same as the ChondroFiller injection — and is used where the defect size, location, or clinical picture calls for it.

Conclusion

ChondroFiller works by adding a self-gelling collagen scaffold within the joint that recruits the body's own progenitor cells to support cartilage repair, while also cushioning worn surfaces and reducing grinding. As a non-surgical injection with a well-established safety record and growing clinical evidence, it represents a meaningful option for patients with early-to-moderate joint wear who wish to avoid or delay surgery. It is not a cure, and individual responses vary.

At the London Cartilage Clinic, specialist assessment considers whether the ChondroFiller injection, a surgical approach, or a combination is most appropriate for each patient's specific joint and circumstances. If you are considering your options, a consultation with a specialist will provide guidance tailored to you.

References

Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.